Tilbake til søkeresultatene

FUGE-Funksjonell genomforskn.i Norg

Immunoproteomics: Development of new cancer diagnostics and therapeutics by using the immunogenic part of the cancer proteome

Tildelt: kr 5,4 mill.

Prosjektleder:

Prosjektnummer:

159148

Prosjektperiode:

2003 - 2008

Geografi:

Fagområder:

Antibodies are long known to be valuable tools for cancer diagnostic. Within the last few yeard, the first antibodies for cancer therapy use have been introduced to the market with excellent results, and possibilities for developing cancer vaccines are w ithin reach. However, identifying tumour associated antigens and antibodies specifically recognizing tumours has proven to be difficult, dure to technical limitations. DNR and Affitech have addressed this problem by combining their expertise in advanced automation and novel technologies in molecular biology. A new method has been developed, which identifies both antibodies and antigens of clinical interest, and a proof of concept could be shown using a model system. The partners now plan to make and e xtensive effort to use this platform for developing new compounds for cancer therapy, diagnosis and vaccination. Preferred cancer areas will be pancreatic cancer, melanoma, lymphoma and prostate cancer. In addition we will investiga

Budsjettformål:

FUGE-Funksjonell genomforskn.i Norg

Temaer og emner

Ingen temaer knyttet til prosjektet